New Prognostic Model Could Predict Leukemia Treatment Success
A study suggests a new laboratory model may help identify treatment risks for adults with relapsed leukemia.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Do you believe personalized diagnostic testing should play a larger role in your medical treatment plan?
Researchers have developed a new prognostic model to better predict treatment response in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Published in 2026, this tool analyzes laboratory blood markers to identify which patients may face higher risks of disease progression.
Why it matters
Tailoring cancer treatment is difficult because responses to targeted therapies vary significantly among patients. This model aims to offer a more precise way to gauge treatment outcomes than existing clinical scoring systems, which may help physicians optimize care strategies for individual patients.
In a study of 177 patients with relapsed or refractory CLL, the model used baseline blood samples to achieve a Harrell C-index of 0.815. While these preliminary findings successfully differentiated patient risk groups, independent validation and clinical trials remain necessary.
The details
The model assesses six laboratory features, including ex vivo sensitivity to drug combinations and the presence of CD8-positive T cells, which were found to correlate with higher progression risk. Unlike some traditional methods, this approach excludes genetic markers like IGHV status or TP53 aberrations. By testing cells against various drug combinations in the laboratory, the researchers aimed to mirror how a patient's cancer might respond to therapies like ibrutinib and venetoclax.
Timeline
2026: Publication of the prognostic model study in the journal HemaSphere.
Health Landscape
Chronic lymphocytic leukemia management relies on clinical scoring systems like the CLL-IPI to estimate survival. This new approach shifts the focus toward functional laboratory markers to address the limitations of existing tools in predicting responses to modern targeted drug regimens.
This research is currently in the experimental phase and does not yet change how CLL is treated in the clinic. If you are navigating a cancer diagnosis, talk to your oncologist about which prognostic tests are currently recommended to help tailor your specific treatment plan.
The takeaway
Predicting how a patient will respond to leukemia therapy remains a complex, evolving field of oncology. Patients and families should maintain open communication with their hematology team regarding the most effective, evidence-based tools available to guide their current care decisions.
Further reading
Learn more about the latest research in blood-related malignancies on our Cancer page.
Source note: This article includes information reported by Ajmc.
Live Poll
Do you believe personalized diagnostic testing should play a larger role in your medical treatment plan?
